Distinct Complication Patterns in Lean Versus Overweight African Adults with Type 2 Diabetes: Implications for Targeted Management
Posted inDiabetes & Endocrinology Neurology news

Distinct Complication Patterns in Lean Versus Overweight African Adults with Type 2 Diabetes: Implications for Targeted Management

African adults with type 2 diabetes who are lean exhibit distinct complication profiles characterized by higher retinopathy and stroke risk but lower hypertension and cardiovascular disease risk compared to their overweight/obese counterparts, indicating a unique diabetes phenotype requiring tailored treatment approaches.
suPAR as a Novel Marker for Residual Inflammatory Risk Beyond hs-CRP in Type 2 Diabetes with Coronary Artery Disease
Posted inCardiology Diabetes & Endocrinology news

suPAR as a Novel Marker for Residual Inflammatory Risk Beyond hs-CRP in Type 2 Diabetes with Coronary Artery Disease

In type 2 diabetes patients with coronary artery disease, suPAR levels remain unchanged despite treatment and independently predict adverse cardiovascular events beyond hs-CRP, highlighting suPAR's potential in identifying treatment-resistant inflammation and refining cardiovascular risk stratification.
Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances
Posted inClinical Updates Diabetes & Endocrinology news

Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances

COMBINE 4 demonstrated that once-weekly IcoSema (icodec+semaglutide) offers superior glycemic control, weight reduction, and reduced hypoglycemia versus daily insulin glargine U100 in insulin-naive type 2 diabetes patients, supported by complementary phase 3 studies on insulin icodec.
Evaluating the Risk of Anterior Ischemic Optic Neuropathy with GLP-1 Receptor Agonists in Type 2 Diabetes: Insights from a Swedish Nationwide Cohort Study
Posted inDiabetes & Endocrinology news Ophthalmology

Evaluating the Risk of Anterior Ischemic Optic Neuropathy with GLP-1 Receptor Agonists in Type 2 Diabetes: Insights from a Swedish Nationwide Cohort Study

A large Swedish cohort study assesses whether glucagon-like peptide-1 receptor agonists increase the risk of anterior ischemic optic neuropathy in type 2 diabetes. Although a borderline elevated relative risk was observed, absolute incidence remained low and confounding factors likely influenced results.